Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload
NCT ID: NCT01369719
Last Updated: 2011-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
138 participants
INTERVENTIONAL
2010-02-28
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)
NCT01996683
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox
NCT03358498
Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox
NCT01905774
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
NCT00564941
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
NCT00061750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Osveral
20 mg/kg oral osveral daily
osveral
receive 20 mg/kg daily orally
desferal
40mg/kg desferal for 6 nights in a week subcutaneously
Desferal
40-50mg/Kg for 6 nights in each week subcutaneously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
osveral
receive 20 mg/kg daily orally
Desferal
40-50mg/Kg for 6 nights in each week subcutaneously
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* More then 2 years old
* Serum Ferritin level \> 1000
* Normal Creatinine and Complete Blood Count (CBC)
Exclusion Criteria
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hormozgan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hormozgan University of Medical Sciences (HUMS)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fariba Mansoori, Resident
Role: PRINCIPAL_INVESTIGATOR
Hormozgan University of Medical Sciences (HUMS)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hormozgan University of Medical Sciences (HUMS)
Bandar Abbas, Hormozgan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Desferal versus Osveral
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.